Navigation Links
New investment fund will advance late-stage vaccines, other global health technologies
Date:9/23/2013

A new investment fund structured by JPMorgan Chase & Co. (NYSE: JPM) and the Bill & Melinda Gates Foundation will, for the first time, allow individual and institutional investors the opportunity to finance late-stage global health technologies that have the potential to save millions of lives in low-income countries.

With $95 million committed by a pioneering group of investors including anchor support from Grand Challenges Canada (funded by the Government of Canada), the German Ministry for Economic Cooperation and Development (acting through KfW) and the Children's Investment Fund Foundation the Global Health Investment Fund ("GHIF" or the "Fund") will help advance the most promising interventions to fight challenges in low-income countries such as malaria, tuberculosis, HIV/AIDS and maternal and infant mortality. With the risk of investing in the clinical development of new technologies partially offset by downside protection from the Gates Foundation and the Swedish International Development Cooperation Agency, the GHIF will seek a financial return for investors by targeting high-impact technologies with sales opportunities in both developed and emerging markets.

"The Global Health Investment Fund demonstrates the potential for innovative collaborations and thoughtful financial structures to mobilize new sources of capital for social challenges," said Jamie Dimon, Chairman and CEO of JPMorgan Chase & Co. "This product brings a diverse group of investors together around the shared objective of developing life-saving technologies in a financially sustainable way."

LHGP Asset Management ("Lion's Head"), a London-based asset manager specializing in sustainable development, will be responsible for originating, managing and exiting GHIF portfolio investments. In addition to the anchor supporters, the Fund's investor group includes organizations such as the International Finance Corporation, GlaxoSmithKline, Merck, The Pfizer Foundat
'/>"/>

Contact: Colleen Harris
colleen@colleenharris.co.uk
44-207-223-4512
Grand Challenges Canada
Source:Eurekalert

Page: 1 2 3 4

Related biology news :

1. ChipCares handheld analyzer attracts one of Canadas largest-ever healthcare angel investments
2. Wexford Science & Technology Makes $150 Million Investment in Wake Forest Innovation Quarter
3. OGIs investment in cytognomix contributes to the Shannon Human Splicing Pipelines success
4. UNC Charlotte researcher leads effort to forecast optimal energy investments
5. Medbox Executes $6 Million Equity Transaction with Private Investment Firm
6. FASEB joins President Obama in urging Congress to sustain investments in research and innovation
7. Nottingham part of £20m investment for UK synthetic biology
8. US investment in biomedical and health research on downward trend
9. AZTI-Tecnalia leads 2 research projects on bluefin tuna with 1.5 million euros investment
10. Amarantus BioSciences to Present at the National Investment Banking Associations (NIBA)122nd Conference in New York City
11. $50 million NSF grant to advance cyberinfrastructure for big data in life sciences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/7/2015)... , July 7, 2015  Based on its ... & Sullivan recognizes Credence ID, LLC with the ... Company of the Year Award. Credence ID has ... in its mission of offering enrollment and identification ... As Credence ID was formed by experts from ...
(Date:7/2/2015)... -- Research and Markets( http://www.researchandmarkets.com/research/jvft55/next_generation ) ... Biometrics Market by Application, Technology, Function & Geography - ... The next generation biometrics market is expected ... of 17.9% between 2015 and 2020 Travel ... Safran SA ( France ), ...
(Date:6/30/2015)... 2015 Genisphere announced Tom ... help further develop Genisphere,s therapeutics capabilities and portfolio. Mr. ... spent much of the last 25 years in leadership ... and Johnson & Johnson. Tom started his career in ... Corporate Finance. He graduated from Dartmouth College with a ...
Breaking Biology News(10 mins):Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 2Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 3Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 4Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 5Next Generation Biometrics Market 2015 - Global Forecast to 2020 with Safran, NEC, 3M Cogent, Fujitsu & Suprema Dominating the $24 Billion Market 2Next Generation Biometrics Market 2015 - Global Forecast to 2020 with Safran, NEC, 3M Cogent, Fujitsu & Suprema Dominating the $24 Billion Market 3Genisphere Appoints New CEO, Thomas Bliss 2Genisphere Appoints New CEO, Thomas Bliss 3
... N.Y. A billion people living in underdeveloped areas ... that survive by residing in and feeding on their ... systemic) illnesses leading to long-term disability. Irah King and ... investigating illnesses caused by these gut-dwelling worms in an ...
... Mo. Americans spend $25 billion a year on ... While the Nutrition Business Journal forecasts that sales of ... over the next five years, scientists still don,t know ... harmful to humans. Now, with a new $7.5 million ...
... Max Planck Institute for Chemical Ecology in Jena, Germany, ... pending for 40 million years. Arum palaestinum ... flies) as pollinators by emitting odor molecules that resemble ... by yeast. The plant accomplishes the illusion of yeast ...
Cached Biology News:Studying illnesses caused by worms: Scientists are learning how immune cells communicate 2MU establishes National Botanical Research Center 2Deceitful lily fools flies 2Deceitful lily fools flies 3
(Date:7/30/2015)... , ... July 30, 2015 , ... ... of a field clinical study of its canine osteoarthritis stem cell product, currently ... Therapeutics (Kansas City, KS) and will be marketed in the US by Aratana. ...
(Date:7/30/2015)... COPENHAGEN, Denmark , July 30, 2015 /PRNewswire/ ... a biotechnology company that applies its innovative TransCon ... announced positive top-line results from a six-month Phase ... of once-weekly TransCon Growth Hormone in 53 treatment-naïve, ... "We are extremely pleased with the ...
(Date:7/30/2015)... ... 2015 , ... GEA's Pony™ NS2006L is a ... to 1500 bar. The sanitary design gauge of the NS2006L is well suited ... Pony™ NS2006L homogenizer is an ideal solution for the processing of nanoparticles, ...
(Date:7/29/2015)... 2015 US-Australian drug discovery company, Novogen Limited ... is committed to progressing its ground-breaking technology platforms to ... to ensure the Company delivers the best value for ... Ross , said the Company currently had an extensive ... discovery programs and academic partnerships and initiatives, and he ...
Breaking Biology Technology:VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 2VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 3Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 5Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 6Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 7GEA Announces the Pony™ NS2006L… a Self-contained, High Pressure Lab Homogenizer for Product Development Ensuring Maximum Efficiency and Safety 2Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 2Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 3Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 4Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 5Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 6Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 7Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 8Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 9Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 10
... LAKE CITY, Feb. 29 DW Healthcare ... announced today the sale of one,of its ... Laboratory,Corporation of America(R) Holdings (LabCorp(R)), one of ... Salt Lake City, UT, Tandem,Labs is a ...
... Feb. 29 /PRNewswire-FirstCall/ - AEterna Zentaris Inc.,(NASDAQ: ... biopharmaceutical company focused on,endocrine therapy and oncology, ... the Company,s Senior Vice President, Administrative & ... accepted the position of,Vice President and Chief ...
... On Friday, February 29, the Johnson & Johnson ... the U.S., designed to improve how,practitioners deliver diabetes care ... be devoted to training community health,professionals., Diabetes affects ... billion a year -- about as much as the ...
Cached Biology Technology:AEterna Zentaris Announces the Departure of SVP, Administrative and Legal Affairs 2MultiVu Video Feed: Johnson & Johnson Diabetes Institute, LLC Launches New Training Center to Improve Community-Based Diabetes Care 2
... 220-240 V, is used for biolistic particle ... device employs an adjustable helium pulse to ... microcarriers from the inner wall of a ... This system has a 2 square-centimeter target ...
The Discovery Series PDQuest 2-D analysis software is used for imaging, analyzing, and databasing two-dimensional electrophoretic gels. The 10-user network license entitles ten users to access data f...
Mouse polyclonal antibody raised against a partial recombinant MHC2TA. NCBI Entrez Gene ID = 4261...
Mouse monoclonal antibody raised against a partial recombinant NR4A2. NCBI Entrez Gene ID = NR4A2...
Biology Products: